Quantitative signal detection using spontaneous ADR reporting
暂无分享,去创建一个
[1] W. Haenszel,et al. Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.
[2] D. J. Finney,et al. stematic Signalling of Adverse Reactions to Drugs , 1974, Methods of Information in Medicine.
[3] A. Sampson,et al. A statistical methodology for postmarketing surveillance of adverse drug reaction reports. , 1988, Statistics in medicine.
[4] M D Rawlins,et al. Spontaneous reporting of adverse drug reactions. II: Uses. , 1988, British journal of clinical pharmacology.
[5] M. Lindquist,et al. Quality criteria for early signals of possible adverse drug reactions , 1990, The Lancet.
[6] I. Edwards,et al. Tachycardia during cisapride treatment. , 1992, BMJ.
[7] Tachycardia during cisapride treatment. , 1992, BMJ.
[8] M. Praus,et al. Alert systems for post-marketing surveillance of adverse drug reactions. , 1993, Statistics in medicine.
[9] I R Edwards,et al. Harmonisation in Pharmacovigilance , 1994, Drug safety.
[10] I. Edwards,et al. Impact and Credibility of the Who Adverse Reaction Signals , 1996 .
[11] M. Lindquist,et al. Risks of non-sedating antihistamines , 1997, The Lancet.
[12] F. Haramburu,et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. , 2003, British journal of clinical pharmacology.
[13] B. Bégaud,et al. Under-reporting of adverse drug reactions Estimate based on a spontaneous reporting scheme and a sentinel system , 1998, European Journal of Clinical Pharmacology.
[14] A. Bate,et al. A Bayesian neural network method for adverse drug reaction signal generation , 1998, European Journal of Clinical Pharmacology.
[15] William DuMouchel,et al. Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .
[16] Andrew Bate,et al. From association to alert—a revised approach to international signal analysis , 1999, Pharmacoepidemiology and drug safety.
[17] Patrick C. Waller,et al. Responding to drug safety issues , 1999, Pharmacoepidemiology and drug safety.
[18] M. Lindquist,et al. A Retrospective Evaluation of a Data Mining Approach to Aid Finding New Adverse Drug Reaction Signals in the WHO International Database , 2000, Drug safety.
[19] R. Meyboom,et al. Anaphylactic Reactions to Proton-Pump Inhibitors , 2000, The Annals of pharmacotherapy.
[20] A. Lansner,et al. Bayesian neural networks with confidence estimations applied to data mining , 2000 .
[21] Miki Yokotsuka,et al. The use of a medical dictionary for regulatory activities terminology (MedDRA) in prescription-event monitoring in Japan (J-PEM) , 2000, Int. J. Medical Informatics.
[22] A. Egberts,et al. Detecting drug–drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs , 2000, European Journal of Clinical Pharmacology.
[23] S. Evans,et al. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports , 2001, Pharmacoepidemiology and drug safety.
[24] D. Wysowski,et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions , 2001, American Journal of Gastroenterology.
[25] M. Braun,et al. Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination. , 2001, Vaccine.
[26] M. Lindquist,et al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study , 2001, BMJ : British Medical Journal.
[27] A. Egberts,et al. Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. , 2001, British journal of clinical pharmacology.
[28] William DuMouchel,et al. Empirical bayes screening for multi-item associations , 2001, KDD '01.
[29] D J Graham,et al. The role of databases in drug postmarketing surveillance , 2001, Pharmacoepidemiology and drug safety.
[30] R. Bright,et al. Automated support for pharmacovigilance: a proposed system , 2002, Pharmacoepidemiology and drug safety.
[31] M. Lindquist,et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.
[32] P. Purcell,et al. Statistical Techniques for Signal Generation , 2002, Drug safety.
[33] Stephen Evans,et al. Statistical Methods of Signal Detection , 2002 .
[34] E. Brown,et al. Effects of Coding Dictionary on Signal Generation , 2002, Drug safety.
[35] M. Lindquist,et al. Signal Selection and Follow-Up in Pharmacovigilance , 2002, Drug safety.
[36] Emma Heeley,et al. Automated Signal Generation in Prescription-Event Monitoring , 2002, Drug safety.
[37] A. Bate,et al. Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs , 2002, European Journal of Clinical Pharmacology.
[38] Peter G. M. van der Heijden,et al. On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios , 2002 .
[39] R. O’Neill,et al. Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA’s Spontaneous Reports Database , 2002, Drug safety.
[40] Patrick C Waller,et al. A model for the future conduct of pharmacovigilance , 2003, Pharmacoepidemiology and drug safety.
[41] M. Lindquist,et al. Assessing the Impact of Drug Safety Signals from the WHO Database Presented in ‘SIGNAL’ , 2003, Drug safety.
[42] P. Waller. Dealing with uncertainty in drug safety: lessons for the future from sertindole , 2003, Pharmacoepidemiology and drug safety.
[43] Violation of Homogeneity: A Methodologic Issue in the Use of Data Mining Tools , 2003, Drug safety.
[44] Nicholas Moore,et al. Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole , 2003, Pharmacoepidemiology and drug safety.
[45] A Lawrence Gould,et al. Practical pharmacovigilance analysis strategies. , 2003, Pharmacoepidemiology and drug safety.
[46] M Lindquist,et al. Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database , 2004, Pharmacoepidemiology and drug safety.
[47] K. Rothman,et al. Measuring drug effects means getting a clearer signal , 2004 .
[48] Stephanie Chung,et al. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms , 2004, European Journal of Clinical Pharmacology.
[49] Robert T. Chen,et al. A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)—United States, 1991–2001 , , 2004, Pharmacoepidemiology and drug safety.
[50] Manfred Hauben,et al. Safety Related Drug-Labelling Changes , 2004, Drug safety.
[51] Marie Lindquist,et al. Data Quality Management in Pharmacovigilance , 2004, Drug safety.
[52] Antoine Egberts,et al. The reporting odds ratio versus the proportional reporting ratio: ‘deuce’ , 2004, Pharmacoepidemiology and Drug Safety.
[53] Kenneth J Rothman,et al. The reporting odds ratio and its advantages over the proportional reporting ratio , 2004, Pharmacoepidemiology and drug safety.
[54] Immune Agranulocytosis and Clarithromycin , 2004, Hematology.
[55] M. Hauben. Application of an Empiric Bayesian Data Mining Algorithm to Reports of Pancreatitis Associated with Atypical Antipsychotics , 2004, Pharmacotherapy.
[56] Robert Ball,et al. Using simulation to assess the sensitivity and specificity of a signal detection tool for multidimensional public health surveillance data. , 2005, Statistics in medicine.
[57] A. Venot,et al. Appraisal of the MedDRA Conceptual Structure for Describing and Grouping Adverse Drug Reactions , 2005, Drug safety.
[58] Frantz Thiessard,et al. Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance , 2005, IEEE Transactions on Information Technology in Biomedicine.
[59] Stefan Arnborg,et al. A bayesian recurrent neural network for unsupervised pattern recognition in large incomplete data sets , 2005, Int. J. Neural Syst..
[60] Andrew Bate,et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis , 2005, The Lancet.
[61] L. Hazell,et al. Under-Reporting of Adverse Drug Reactions , 2006, Drug safety.
[62] A. Bate,et al. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events , 2006, Statistics in medicine.
[63] G. Niklas Norén,et al. Duplicate detection in adverse drug reaction surveillance , 2007, Data Mining and Knowledge Discovery.
[64] M. Kulldorff,et al. Early detection of adverse drug events within population‐based health networks: application of sequential testing methods , 2007, Pharmacoepidemiology and drug safety.
[65] Robert Ball,et al. Effects of Stratification on Data Mining in the US Vaccine Adverse Event Reporting System (VAERS) , 2008, Drug safety.
[66] Johan Hopstadius,et al. Impact of Stratification on Adverse Drug Reaction Surveillance , 2008, Drug safety.
[67] G. Niklas Norén,et al. Temporal pattern discovery for trends and transient effects: its application to patient records , 2008, KDD.
[68] Stephen J W Evans. Stratification for Spontaneous Report Databases , 2008, Drug safety.
[69] R. Sundberg,et al. A statistical methodology for drug–drug interaction surveillance , 2008, Statistics in medicine.
[70] Richard Platt,et al. Early adverse drug event signal detection within population‐based health networks using sequential methods: key methodologic considerations , 2009, Pharmacoepidemiology and drug safety.